



PATENT
Attorney Docket No. 05031.0003.CNUS02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant(s): Lester Lau
App. No.: 10/053,753
Conf. No.: 6127
Filing Date: January 22, 2002
Title: EXTRACELLULAR MATRIX
SIGNALLING MOLECULES
Art Unit: 1632
Examiner: Woitach, Joseph F.

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date:

01/06/05

Date


Teddy C. Scott, Jr., Ph.D.
Registration No. 53,573

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 and 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, Applicants call to the attention of the Examiner the references listed on the attached Form PTO/SB/08B. It is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08B be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g), this Information Disclosure Statement is not to be construed as a representation that a search has been made. In accordance with 37 C.F.R. § 1.97(h), this Information Disclosure Statement is not to be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

01/18/2005 MBLANCO 00000007 083038 10053753


01 FC:1806 180.00 DA

This Information Disclosure Statement is being filed prior to the receipt of a final action under 37 C.F.R. §1.113, a notice of allowance under 37C.F.R. §1.311, or an action that otherwise closes prosecution in this application and accompanied with the fee of \$180.00 set forth in §1.17(p), and hence is believed to be timely filed in accordance with 37 C.F.R. §1.97(c)(2). No other fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any additional fees under 37 C.F.R. §§1.16 to 1.21 be deemed necessary for any reasons relating to this document, the Commissioner is hereby authorized to deduct the fees from Howrey Simon Arnold & White, LLP Deposit Account 08-3038 referencing docket number 05031.0003.CNUS02.

Respectfully submitted,

HOWREY SIMON ARNOLD & WHITE, LLP


By:



Teddy C. Scott, Jr., Ph.D.
Registration No.: 53,573
Customer No.: 22930

Dated: January 6, 2005

HOWREY SIMON ARNOLD & WHITE, LLP
321 N. Clark Street, Suite 3400
Chicago, IL 60661
(312) 595-1239 (main)
(312) 846-5621 (direct)
(312) 595-2250 (fax)



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

				Complete if Known
Application Number	10/053,753			
Filing Date	January 22, 2002			
First Named Inventor	Lester Lau			
Group Art Unit	1632			
Examiner Name	Joseph T. Woitach			
Attorney Docket Number	05031.0003.CNUS02			

Sheet	1	of	1	
-------	---	----	---	--

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	C42	Brooks P., et al., "Subtractive Immunization Yields Monoclonal Anitbodies that Specifically Inhibit Metastasis," The Journal of Cell Biology, Vol. 122, No. 6, pp. 1351-1359 (September 1993)	
	C43	Williams C., et al., "Subtractive Immunization Techniques for the Production of Monoclonal Antibodies to Rare Antigens," BioTechniques, Vol. 12, No. 6, pp. 842-847 (1992)	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.